Previous 10 | Next 10 |
United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human ...
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. United Therapeutics will host a public webcast Wednesday, November 1, 2023, at 9:00 a.m. Eastern Time. The ...
2023-10-23 03:35:36 ET Summary United Therapeutics' strategic pivot to Tyvaso DPI aims to thwart generic competition through enhanced efficacy and patient compliance. Robust liquidity and operational cash flow; low likelihood of external financing required in the near term. In...
2023-10-22 12:25:39 ET Summary United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a competitive advantage with a diverse and unique product portfolio, driving revenue and profit growth. ...
2023-10-20 16:32:32 ET More on Liquidia Key Upcoming Catalysts Could Finally Turn Liquidia Profitable Liquidia Corporation (LQDA) Q2 2023 Earnings Call Transcript Liquidia adds second indication for Yutrepia marketing application Liquidia falls as U.S. appeal...
2023-10-10 14:44:04 ET More on MannKind MannKind's Robust Patient Demand, Operational Efficiency To Drive Revenue Beyond Q2 2023 MannKind Corporation 2023 Q2 - Results - Earnings Call Presentation MannKind Corporation (MNKD) Q2 2023 Earnings Call Transcript S...
2023-10-05 22:21:27 ET Summary I argue that financial professionals should pay more attention to large-cap stocks outside the S&P 500, as they often offer missed opportunities for investors. The S&P 500 is not a purely passive index, as it is actively managed and has speci...
2023-10-03 17:46:09 ET More than 80 stocks were identified by Morgan Stanley as potentially having technical pressure due to tax loss selling. A Morgan Stanley U.S. Equity Strategy report, published on Monday, showed 81 stocks that could have performance pressures due to market selling ...
Second UHeart™ recipient recovering after a successful transplant UThymoKidney™ demonstrates normal function during a 61-day study Human xenotransplant clinical studies could begin in 2025 United Therapeutics Corporation (Nasdaq: UTHR ), a public benefi...
Report available at corporateresponsibility.unither.com United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation ( PBC ), today announced the release of its 2023 Corporate Responsibility and Public Benefit Report covering its 2022 progress toward its pub...
News, Short Squeeze, Breakout and More Instantly...
United Therapeutics Corporation Company Name:
UTHR Stock Symbol:
NASDAQ Market:
United Therapeutics Corporation Website:
United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. ...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
2024-07-11 06:30:06 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for UTHR on July 11, 2024 04:53AM ET. The previous analyst recommendation was Overweight. UTHR was trading at $329.25 at issue of the analyst recommendation. The overall analyst consensus : ...